U.S. markets open in 4 hours 16 minutes

  • S&P Futures

    4,441.25
    +0.75 (+0.02%)
     

  • Dow Futures

    35,419.00
    +47.00 (+0.13%)
     

  • Nasdaq Futures

    15,004.75
    -14.75 (-0.10%)
     

  • Russell 2000 Futures

    2,249.20
    +0.50 (+0.02%)
     

  • Crude Oil

    69.31
    +0.06 (+0.09%)
     

  • Gold

    1,757.70
    +4.40 (+0.25%)
     

  • Silver

    23.43
    -0.05 (-0.23%)
     

  • EUR/USD

    1.1748
    +0.0003 (+0.02%)
     

  • 10-Yr Bond

    1.3390
    0.0000 (0.00%)
     

  • Vix

    16.13
    -0.66 (-3.93%)
     

  • GBP/USD

    1.3864
    -0.0004 (-0.03%)
     

  • USD/JPY

    110.3880
    -0.0300 (-0.03%)
     

  • BTC-USD

    45,053.00
    -1,053.93 (-2.29%)
     

  • CMC Crypto 200

    1,122.72
    -9.12 (-0.81%)
     

  • FTSE 100

    7,209.73
    -10.41 (-0.14%)
     

  • Nikkei 225

    28,015.02
    -55.49 (-0.20%)
     

Global $22.21 Bn Vitamin and Minerals Markets to 2025 & 2030: Energy & Weight Management, General Health, Bone & Joint, Gastrointestinal Health, Immunity, Cardiac Health, Diabetes, Anti-cancer

Research and Markets
·5 min read

Dublin, Aug. 12, 2021 (GLOBE NEWSWIRE) -- The "Vitamin and Minerals Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering.

The global vitamin and minerals market is expected to decline from $18.14 billion in 2020 to $17.54 billion in 2021 at a compound annual growth rate (CAGR) of -3.3%. The market is expected to reach $22.21 billion in 2025 at a CAGR of 6%.

Major players in the vitamins and mineral supplements market are Salus Haus, Pfizer, Daiichi Sankyo, Amway, Eisai, Sanofi, GNC, CSPC Pharmaceutical Group, DSM, and Otsuka Holdings Co. Ltd.

The vitamins and mineral supplements market consists of sales of vitamins and mineral supplements that improve the health and wellness of the population. The sales comprise of revenue generated by the establishments manufacturing vitamins and minerals. Vitamins and mineral supplements are available without a prescription and come in tablets, powders or liquids and provide sufficient vital nutrients and minerals that preserve or boost an individual's health.

The disruptions in supply chains for the production of supplements are a key factor hampering the growth of the vitamins and mineral supplement market. COVID-19 outbreak has led to restrictive containment measures involving social distancing and remote working, and the closure of industries and other commercial activities.

The entire supply chain from production to international trade has been impacted. The economic crisis due to COVID-19 is also impacting dietary supplements by disrupting distribution networks. The supplements, which are economically important, have a fragile supply chain and failure in any stage of the supply chain from farms to dealers, haulers and distributors to manufacturers-can disrupt the entire chain.

International Food Policy Research Institute (IFPRI) has gathered evidence of major disruptions to livestock production in China, and vegetables and fruits in Ethiopia, whereas Indian news reported a full-blown collapse in the production of dairy products, which is especially worrying the countries where milk and milk products remain key sources of primary nutrients for young children. Therefore, disruptions in supply chains for nutrient-rich foods are expected to hinder the growth of the vitamins and mineral supplement market.

In April 2020, American Regent Inc, a US manufacturer of pharmaceuticals for human and veterinary use with manufacturing sites in New York and Ohio, acquired Daiichi Sankyo for an undisclosed amount. This acquisition increases American Regent's production and provides the opportunity to explore other products to manufacture, allowing the company to continue to find innovative ways of responding to customer needs. Daiichi Sankyo is a pharmaceutical company with its corporate origin in Japan.

The growing use of dietary supplements in the modern lifestyle is a key factor driving the growth of the vitamins and mineral supplement market.

Nutrition plays an important role in maintaining immune system balance, and supplementation with the micronutrients such as vitamins C and D, Zinc and omega fatty acids within recommended upper safety limits is a safe, effective and low-cost strategy to help support optimal immune function in patients fighting COVID-19 and other respiratory tract diseases. In the case of COVID-19 patients, a variety of high-protein and fibre foods, including cookies, bread and rolls, have been developed by the Indian Research Institute.

A nutritional focus on the immune system could help minimize the impact of the current COVID-19 pandemic and other infections. Therefore, the implementation of dietary supplements in the lifestyle is expected to drive the growth of the vitamins and mineral supplement market.

The consumer preference moving towards organic supplements is a key trend in the vitamins and mineral supplement market. There was a suggested transition towards vegan & organic food in 2020, and this trend will shortly become a lifestyle for many people as COVID-19 is taking the world by storm.

As a lot of people globally believe that the COVID crisis is associated with the consumption of animal meat, people will become more cautious of the food they consume and this can result in a significant rise in the demand for organic and vegan food products. Many small and medium enterprises have started to promote plant-based goods and diets in the product space. The coronavirus pandemic is accelerating the trend for organic food supplements.

Key Topics Covered:

1. Executive Summary

2. Vitamins and Mineral Supplement Market Characteristics

3. Vitamins and Mineral Supplement Market Trends And Strategies

4. Impact Of COVID-19 On Vitamins and Mineral Supplement

5. Vitamins and Mineral Supplement Market Size And Growth
5.1. Global Vitamins and Mineral Supplement Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Vitamins and Mineral Supplement Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Vitamins and Mineral Supplement Market Segmentation
6.1. Global Vitamins and Mineral Supplement Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Multivitamin

  • Single Vitamin

  • Multi Mineral

  • Single Mineral

6.2. Global Vitamins and Mineral Supplement Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Energy & Weight Management

  • General Health

  • Bone & Joint Health

  • Gastrointestinal Health

  • Immunity

  • Cardiac Health

  • Diabetes

  • Anti-cancer

  • Others

6.3. Global Vitamins and Mineral Supplement Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Pharmacies & Drug Stores

  • Supermarkets & Hypermarkets

  • Online Channels

6.4. Global Vitamins and Mineral Supplement Market, Segmentation By End-User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Adults

  • Geriatric

  • Pregnant Women

  • Children

  • Infants

7. Vitamins and Mineral Supplement Market Regional And Country Analysis
7.1. Global Vitamins and Mineral Supplement Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Vitamins and Mineral Supplement Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Companies Mentioned

  • Salus Haus

  • Pfizer

  • Daiichi Sankyo

  • AMWAY

  • Eisai

  • Sanofi

  • GNC

  • CSPC Pharmaceutical Group

  • DSM

  • Otsuka Holdings Co. Ltd

  • Puritan's Pride

  • Pharmavite

  • Jamieson

  • Webber Naturals

  • Hainan Yangshengtang

  • Nature's Bounty

  • CCMP Capital

  • Pharmavite

  • Suntory Holdings Ltd

  • Glanbia PLC

  • Glaxosmithkline PLC

  • Abbott Laboratories

  • Bayer AG

  • Puritan's Pride

  • General Nutrition CentersInc.

  • Webber Naturals

  • CSPC Pharmaceutical Group

  • Hainan Yangshengtang

For more information about this report visit https://www.researchandmarkets.com/r/9x0qw0

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Recommended Stories

  • FDA set to approve third COVID-vaccine dose for those with weakened immune systems: report

    The U.S. Food and Drug Administration is expected to authorize a third dose of the COVID-19 vaccine for those with weakened immune systems as soon as Thursday, the New York Times reported Wednesday night.

  • Why Shares of BioNTech Were Falling Today

    Shares of BioNTech (NASDAQ: BNTX) were down nearly 7% today after two studies of more than 50,000 patients in the Mayo Clinic Health System showed rival Moderna's (NASDAQ: MRNA) vaccine might be more effective against the troublesome delta variant of the SARS-CoV-2 coronavirus. The effectiveness of BioNTech's vaccine, developed with Pfizer (NYSE: PFE), was only 42% during July, according to the study, compared to 76% for Moderna. A second study showed nursing home residents generated stronger immune responses after the Moderna vaccine than after BioNTech's.

  • The Dawn Of A New Era In Deepwater Drilling

    A new era has dawned in the deepwater drilling industry, and major players are willing to risk billions to reap the rewards

  • Can Pfizer Seize Share in This Multibillion-Dollar Market?

    The answer ultimately depends on whether the uncertainty plaguing JAK inhibitors resolves positively.

  • If You Got Pfizer, This New Study Is a "Wakeup Call," Biden Aide Says

    After finally getting vaccinated, you may have felt like your days of worrying about catching COVID were behind you. Unfortunately, the Delta variant has complicated things. As the more contagious strain of the virus—now dominant in the U.S.—continues to spread far and wide, vaccinated people are worried about the potential for breakthrough COVID infections. And while the vast majority of these cases are thankfully mild, one recent study found that those who got the Pfizer vaccine may be even le

  • Booster Doses for the Elderly Are Coming, Analyst Says. Friday Is a Key Date.

    Jefferies analyst Michael Yee expects the CDC's vaccine advisory committee to recommend booster doses of Pfizer’s vaccine for some people on Friday.

  • Is Gold Heading To $5,000?

    Equities and assets have significantly increased over the past year, but this run could be on the first leg, and gold might just emerge as one of the biggest winners

  • U.S. FDA set to authorize COVID-19 vaccine boosters for immunocompromised patients - NBC News

    The U.S. Food and Drug Administration is expected to authorize a third booster dose of COVID-19 vaccines by Pfizer Inc and Moderna Inc for people with weakened immune systems, NBC News reported on Wednesday. The health agency will amend the emergency use authorizations for the two vaccines as soon as Thursday to allow immunocompromised people to get an additional dose, the report said, citing people familiar with the matter. The agency is closely monitoring data as it becomes available from studies administering an additional dose of the authorized COVID-19 vaccines to immunocompromised individuals, FDA spokesperson Abby Capobianco said in a statement.

  • The FDA Rejects FibroGen Drug. The Damage to the Stock Is Already Done.

    The long-expected rejection of FibroGen’s application for approval of its drug roxadustat finally arrived early Wednesday morning.

  • Oil Steadies as Investors Bet Demand Rebound Can Withstand Delta

    (Bloomberg) -- Oil steadied after a two-day advance as investors bet the global demand recovery will remain intact despite the latest wave of Covid-19 that’s led to tighter restrictions on movement in many countries.Futures in New York traded near $69 a barrel after rising more than 4% over the previous two sessions. While Goldman Sachs Group Inc. estimated the net impact of the delta virus variant on oil demand is likely to be moderate, the International Energy Agency cut its global consumption

  • If You Got This Vaccine, Your Risk of COVID After Vaccination May Be Higher

    From celebrities like Reba McEntire to those vacationing in a Massachusetts beach town, breakthrough COVID infections have hit people across the U.S. over the past few months. And despite data showing that getting a post-vaccination case of COVID is still uncommon, it has become a significant concern amid the country's continued fight against the virus. Studies have shown that anything from age to prior health conditions to emerging variants could cause you to have a weakened immune response to

  • 5 Infrastructure Stocks That Look Like Bargains as Senate Passes Bill

    Most construction-related stocks have run up in anticipation of the passage of the $1 trillion bill. But engineering and inspection firms’ shares still seem well-priced.

  • Why Fulcrum Therapeutics Popped Again on Tuesday

    Compelling clinical-trial data that could validate the company's unique approach to new drug development inspired a slew of analyst upgrades.

  • How Tesla's Vehicle Deliveries Are Likely to Soar More Than 50% This Year

    The electric-car maker's deliveries have grown at uncanny rates for years -- and 2021 looks like it will be no exception.

  • EU looking into new possible side-effects of mRNA COVID-19 shots

    Europe’s drug regulator said on Wednesday it was looking into three new conditions to assess whether they may be possible side effects related to COVID-19 vaccines from Pfizer and Moderna following a small number of cases.

  • 3 Pharma Stocks to Buy in August

    Here's why they chose Bayer (OTC: BAYR.Y), Eli Lilly (NYSE: LLY), and Pfizer (NYSE: PFE). Zhiyuan Sun (Bayer): Investing guru Warren Buffett once said, "When there's blood in the streets, you buy." The quote could not be more applicable to shares of Bayer.

  • China Goes After Online Insurance in Widening Crackdown

    (Bloomberg) -- China’s banking and insurance watchdog is stepping up scrutiny of the nation’s insurance technology platforms, widening a regulatory dragnet that has roiled global investors.The regulator has ordered companies and local agencies to curb improper marketing and pricing practices, and step up user privacy protection, according to a notice seen by Bloomberg News. It encouraged companies to address these issues voluntarily and said those that failed to comply would face “severe punishm

  • Report: FDA expected to OK 3rd vaccine dose for the immunocompromised

    Report: FDA expected to OK 3rd vaccine dose for the immunocompromised

  • Third dose of Moderna COVID vaccine helps protect transplant patients, study finds

    A third dose of Moderna’s COVID-19 vaccine substantially improved protection for organ transplant recipients whose weak immune systems don't always rev up enough with the standard two shots, Canadian researchers reported Wednesday.

  • 3 Nasdaq 100 Stocks to Buy Hand Over Fist in August

    Despite handily outperforming the broader market, the Nasdaq 100 is home to three exceptional bargains.